CAMBRIDGE, Mass.--(BUSINESS WIRE)--ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that the United States Adopted Names (USAN) Council and the World Health Organization (WHO) have approved the name “deforolimus” for AP23573, ARIAD’s proprietary mTOR inhibitor. ARIAD and Merck & Co., Inc. have a global collaboration to jointly develop and commercialize deforolimus for use in cancer. The Phase 3 trial of oral deforolimus in patients with metastatic sarcoma is expected to begin this quarter.
